The results also echo a long documented finding in depression treatment research across the age span — namely, that there is a high
placebo response rate, which can exceed 50 %.
Not exact matches
Hep C patients being treated for opioid addiction achieved high
rates of sustained virologic
response after 12 weeks of therapy with elbasvir - grazoprevir compared to those taking
placebo for 12 weeks before beginning the drug treatment.
Study results show the
response rate for all treated patients with sofosbuvir was 78 percent compared to 0 percent in participants treated with
placebo agents.
Tofacitinib 5 and 10 mg twice - daily was superior to
placebo for ACR20
response rates at week 2 (p < 0.001 and p < 0.0001 respectively) with
responses maintained to 12 months.
The two groups were evenly matched with regard to
rates of
response to induction therapy (44 % complete or partial
response in the pemetrexed arm vs. 42 %
placebo arm).
At the same time, Chaibi said, studies of pain medication typically see high
response rates to the
placebo, too.
Interestingly, open label fluoxetine treatment of
placebo non-responders yielded a 24 %
response rate.